Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Context Therapeutics

31/07/2026 21:07

Context Therapeutics Inc CNTX.OQ CNTX.O is expected to  show no change in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Context Therapeutics Inc is for a loss of 9 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Context Therapeutics Inc is $5.00, about 723.3% above its last closing price of $0.61
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.13
-0.12
-0.09
Beat
23.3
Dec. 31 2026
-0.12
-0.11
-0.14
Missed
-32
Sep. 30 2025
-0.09
-0.09
-0.10
Missed
-6.1​
Jun. 30 2025
-0.06
-0.06
-0.09
Missed
-47.1
​​Mar. 31 2025
-0.06
-0.06
-0.05
Beat
13.5
Dec. 31 2024
-0.16
-0.09
-0.04
Beat
56.9​
Sep. 30 2024
-0.16
-0.10
-0.22
Missed
-109.5
Jun. 30 2024
-0.08
-0.07
-0.04
Beat
46.7
This summary was machine generated July 31 at 20:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)